Endolife Speciality Hospitals

The trials here

What the 11 trials at this site are about, from their registry records.

Conditions

• Obesity8 trials
• Type 2 diabetes6 trials
• Chronic kidney disease2 trials
• Obstructive sleep apnoea2 trials
• Stroke2 trials
• Coronary artery disease1 trial
• Fatty liver disease (MASLD/MASH)1 trial
• Heart failure1 trial
• Osteoarthritis1 trial
• Peripheral artery disease1 trial

Phase

• Phase 311 trials

Status

• Not yet recruiting5 trials
• Recruiting3 trials
• Active, not recruiting2 trials
• Completed1 trial

Lead sponsor

• Eli Lilly and Company11 trials

Running trials

• Not yet recruiting

  A Study of EloraTZP in Adult Participants With Obesity Without Type 2 Diabetes

  NCT07881432· Phase 3· Eli Lilly and Company· Source

  Contact: Kongara Srikanth (principal investigator)

• Not yet recruiting

  A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, Type 2 Diabetes, and Increased Cardiovascular Risk

  NCT07900633· Phase 3· Eli Lilly and Company· Source

  Contact: Anjith VUPPUTURI (principal investigator)

• Recruiting

  A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity

  NCT07794579· Phase 3· Eli Lilly and Company· Source

  Contact: Kongara Srikanth (principal investigator)

• Recruiting

  A Study of Orforglipron (LY3502970) Compared With Dulaglutide in Pediatric Participants With Type 2 Diabetes

  NCT07668336· Phase 3· Eli Lilly and Company· Source

  Contact: Kongara Srikanth (principal investigator)

• Recruiting

  A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight

  NCT07369011· Phase 3· Eli Lilly and Company· Source

  Contact: GADDIPATI BABU (principal investigator)

• Recruiting

  A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes

  NCT07321886· Phase 3· Eli Lilly and Company· Source

  Contact: Kongara Srikanth (principal investigator)

• Recruiting

  A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)

  NCT07241390· Phase 3· Eli Lilly and Company· Source

  Contact: Anjith VUPPUTURI (principal investigator)

• Recruiting

  A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)

  NCT07165028· Phase 3· Eli Lilly and Company· Source

  Contact: Kongara Srikanth (principal investigator)

• Active, not recruiting

  The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)

  NCT06383390· Phase 3· Eli Lilly and Company· Source

• Active, not recruiting

  A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities

  NCT05869903· Phase 3· Eli Lilly and Company· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Obesity5 recruiting
• Type 2 diabetes4 recruiting
• Chronic kidney disease1 recruiting
• Fatty liver disease (MASLD/MASH)1 recruiting
• Obstructive sleep apnoea1 recruiting
• Stroke1 recruiting

Closed trials

• Completed

  A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight

  NCT05929066· Phase 3· Eli Lilly and Company· Source